ELOX (Eloxx Pharmaceuticals) Altman Z2-Score: -207.79 (As of Jun. 27, 2026)


ELOX Eloxx Pharmaceuticals Inc ELOX
17 GF Score
Price $12.05
! 1 Warning Sign
View Full Analysis

What is Eloxx Pharmaceuticals Altman Z2-Score?

Eloxx Pharmaceuticals ELOX +5.57% 17 Altman Z2-Score is -207.79 as of Jun. 27, 2026. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 1,398 Biotechnology companies, Eloxx Pharmaceuticals ranks worse than 96.35% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Eloxx Pharmaceuticals has a Altman Z2-Score of -207.79, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Eloxx Pharmaceuticals's Altman Z2-Score or its related term are showing as below:

ELOX' s Altman Z2-Score Range Over the Past 10 Years
Min: -699.4   Med: -50.19   Max: -0.5
Current: -207.79

During the past 13 years, Eloxx Pharmaceuticals's highest Altman Z2-Score was -0.50. The lowest was -699.40. And the median was -50.19.


Eloxx Pharmaceuticals  (NAS:ELOX) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Eloxx Pharmaceuticals Altman Z2-Score Related Terms


Eloxx Pharmaceuticals Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals Altman Z2-Score Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.05 -54.47 -699.40 -381.79 -207.79

Eloxx Pharmaceuticals Semi-Annual Data
Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.05 -54.47 -699.40 -381.79 -207.79

ELOX vs CPMV, OGEN, CASIF: Altman Z2-Score Comparison

For the Biotechnology subindustry, Eloxx Pharmaceuticals's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eloxx Pharmaceuticals Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's Altman Z2-Score falls into.


ELOX
17GF Score
Eloxx Pharmaceuticals Inc ELOX
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eloxx Pharmaceuticals Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Eloxx Pharmaceuticals's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-2.2594+3.26*-57.0361+6.72*-0.9385+1.05*-0.6932
=-207.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was $5.27 Mil.
Total Current Assets was $5.27 Mil.
Total Current Liabilities was $17.18 Mil.
Retained Earnings was $-300.58 Mil.
Pre-Tax Income was $-6.00 Mil.
Interest Expense was $-1.05 Mil.
Total Liabilities was $17.18 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(5.27 - 17.177)/5.27
=-2.2594

X2=Retained Earnings/Total Assets
=-300.58/5.27
=-57.0361

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-5.995 - -1.049)/5.27
=-0.9385

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(-11.907 - 0)/17.177
=-0.6932

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Eloxx Pharmaceuticals has a Altman Z2-Score of -207.79 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of -207.79 mean?
Eloxx Pharmaceuticals (ELOX) has a Altman Z2-Score of -207.79 as of Jun. 27, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Eloxx Pharmaceuticals and its competitors. According to the industry distribution chart, Eloxx Pharmaceuticals ranks #1347 out of 1398 companies in the Biotechnology industry, placing it in the top 96.4%.
Is Eloxx Pharmaceuticals' Altman Z2-Score too high?
Eloxx Pharmaceuticals' current Altman Z2-Score is -207.79. Based on the distribution chart, Eloxx Pharmaceuticals ranks #1347 out of 1398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' Altman Z2-Score compare to CPMV and OGEN?
According to the Biotechnology industry distribution chart, Eloxx Pharmaceuticals ranks #1347 out of 1398 companies for Altman Z2-Score. This places Eloxx Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Eloxx Pharmaceuticals and its competitors. Eloxx Pharmaceuticals's current Altman Z2-Score is -207.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current Altman Z2-Score of -207.79. The current Altman Z2-Score is -207.79. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current Altman Z2-Score is -207.79 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
17GF Score

Get the complete analysis for ELOX

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.05
Price